01—Abstract
Summary
Summary of the 10-K filed February 27, 2020. Cited figures are marked; the original filing is the authoritative source.
Fortive Corporation's 2019 Form 10-K reports sales of $7.32 billiona for 2019, up from $6.45 billion in 2018, with net earnings from continuing operations of $725.4 million (diluted EPS of $1.93) versus $918.3 million (diluted EPS of $2.52) a year earlier.
Operating profit fell to $1.00 billionb from $1.18 billion, with the operating profit margin decreasing 460 basis points to 13.7%. Management attributes the margin decline mainly to the net dilutive effect of acquired businesses, including amortization, along with transaction costs related to the planned separation. Sales growth was driven by acquisitions (13.2%) more than by existing businesses (2.0%), and currency reduced sales by 1.8%.
The company's largest 2019 move was the $3.9 billionc cash acquisition program, including the Advanced Sterilization Products business of Johnson & Johnson for $2.7 billion, plus Intelex, Pruftechnik and Censis. Funding came largely from a $1.4 billion convertible note issuance and $1.0 billion and $500 million term loans. Long-term debt, including the current portion, reached approximately $6.3 billion at December 31, 2019, up from $3.4 billion, and goodwill and other intangibles totaled about $12.2 billion.
Total assets rose to $17.44 billiond from $12.91 billion. Fortive announced in September 2019 its intention to separate into two independent public companies: a Fortive industrial technology company and Vontier, which would hold the Transportation Technologies and Franchise Distribution platforms.
The separation is expected to be completed in the second half of 2020. The filing also notes the company expects sales from existing businesses to continue growing in 2020, while monitoring trade uncertainty with China and the coronavirus.
02—Key points
Key Highlights
- Sales of $7.32 billion in 2019, up from $6.45 billion in 2018; acquisitions contributed 13.2 percentage points of growth versus 2.0% from existing businesses.
- Operating profit declined to $1.00 billion from $1.18 billion; operating profit margin fell 460 basis points to 13.7%, driven mainly by acquired-business amortization and dilution and separation-related transaction costs.
- Diluted EPS from continuing operations was $1.93, down from $2.52; net earnings from continuing operations were $725.4 million versus $918.3 million.
- Acquired Advanced Sterilization Products from Johnson & Johnson for $2.7 billion in April 2019, and completed several other 2019 acquisitions for $3.9 billion in aggregate net cash consideration.
- Long-term debt, including current portion, rose to approximately $6.3 billion, funded by a $1.4 billion 0.875% convertible note offering and new term loans.
- Announced plan to separate into two public companies, with the Transportation Technologies and Franchise Distribution businesses forming Vontier; completion is expected in the second half of 2020.
- Gross profit margin was 50.3%, down from 51.5%, and SG&A rose to 30.3% of sales from 26.8%.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2019, Fortive kept $0.16.
- Revenue$4.56B100.0%
- Cost of revenue−$2.08B45.6%
- Gross profit$2.48B54.4%
- Operating costs−$2.04B44.7%
- Operating income$443.9M9.7%
- Interest, other & tax$295.0M6.5%
- Net income$738.9M16.2%
Where FY2019 revenue went
$4.56B- Cost of revenue: $2.08B, 46% of revenue
- SG&A: $1.72B, 38% of revenue
- Operating income: $443.9M, 9.7% of revenue
- R&D: $320.3M, 7.0% of revenue
Kept 9.7% as operating incomeOperating income $443.9M · 9.7%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2019filed February 27, 2020Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $4.56B$3.80B | +20.1% |
| Cost of Revenue | $2.08B$1.61B | +28.9% |
| Gross Profit | $2.48B$2.19B | +13.6% |
| R&D Expenses | $320.30M$278.10M | +15.2% |
| SG&A Expenses | $1.72B$1.26B | +36.1% |
| Operating Income | $443.90M$645.30M | −31.2% |
| Interest Expense | $142.60M$77.20M | +84.7% |
| Net Income | $738.90M$2.91B | −74.6% |
| EPS (Basic) | $1.99$8.33 | −76.1% |
| EPS (Diluted) | $1.97$8.21 | −76.0% |
| Shares Outstanding (Basic) | 335.80M345.50M | −2.8% |
| Shares Outstanding (Diluted) | 340.00M350.70M | −3.1% |
05—Questions
Frequently Asked Questions
How did Fortive perform financially in 2019?
Sales rose 13.4% to $7.32 billion, but net earnings from continuing operations fell to $725.4 million from $918.3 million. Operating profit margin decreased 460 basis points to 13.7%, mainly due to acquisition-related amortization and dilution and transaction costs.
What drove the growth in 2019 sales?
Acquisitions contributed 13.2 percentage points of the 13.4% total revenue growth, while sales from existing businesses grew 2.0%. Currency exchange rates reduced sales growth by 1.8%. Professional Instrumentation sales rose 21.1% and Industrial Technologies sales rose 3.4%.
What is the planned separation into two companies?
Fortive announced on September 4, 2019 its intention to separate into two independent, publicly traded companies. Fortive would retain the Fortive name and focus on connected workflow solutions, while Vontier would hold the Transportation Technologies and Franchise Distribution platforms. The separation is expected to be completed in the second half of 2020.
How did Fortive finance its 2019 acquisitions?
The company issued $1.4 billion of 0.875% convertible senior notes due 2022, drew a $1.0 billion 364-day delayed-draw term loan and a $500 million 364-day term loan, and used commercial paper. Long-term debt rose from $3.4 billion to $6.3 billion.
What are the main risks highlighted in the filing?
The filing highlights risks including global economic conditions, intense competition, U.S.-China trade relations, the ability to complete acquisitions at attractive prices, goodwill impairment on about $12.2 billion of goodwill and intangibles, currency fluctuations, the rising debt level and its covenants, and the planned separation not achieving its intended benefits.
06—Continue